Literature DB >> 25288416

Hospitalizations and costs associated with hepatitis C and advanced liver disease continue to increase.

Fujie Xu1, Xin Tong2, Andrew J Leidner3.   

Abstract

Disease burden models have predicted worsening morbidity of liver disease caused by hepatitis C in the United States. The aim of this study was to determine the trend in hospitalizations caused by hepatitis C and advanced liver disease. We analyzed data for the period 2004-11 from the Nationwide Inpatient Sample, the largest nationwide all-payer hospital inpatient care database. Hospitalization rates for hepatitis C per 100,000 people increased significantly from 4.76 in 2004-05 to 13.81 in 2010-11-an increase of 190 percent. Hospitalization rates for advanced liver disease also increased, particularly for hepatorenal syndrome (93 percent) and portal hypertension (62 percent). Hepatitis C was the principal diagnosis for 64,867 hospitalizations in 2010-11, resulting in a total charge of $3.5 billion. We found nationwide trends in increasing morbidity and medical costs for advanced liver disease associated with hepatitis C. Our findings suggest that hepatitis C is a public health problem and has been growing in magnitude in recent years. Stakeholders and policy makers should implement both recommended screenings for people born in the period 1945-65 and more effective treatment for hepatitis C, which have the potential to reverse the rising morbidity and costs of hepatitis C. Project HOPE—The People-to-People Health Foundation, Inc.

Entities:  

Keywords:  Cost of Health Care; Hospitals

Mesh:

Year:  2014        PMID: 25288416     DOI: 10.1377/hlthaff.2014.0096

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  18 in total

1.  Short-Term Incidence of Sequelae of HCV Infection Among Medicaid Beneficiaries in Oregon.

Authors:  Kazuaki Jindai; Courtney Crawford; Ann R Thomas
Journal:  Public Health Rep       Date:  2018-12-03       Impact factor: 2.792

2.  Estimating the Number of Patients Infected With Chronic HCV in the United States Who Meet Highest or High-Priority Treatment Criteria.

Authors:  Fujie Xu; Andrew J Leidner; Xin Tong; Scott D Holmberg
Journal:  Am J Public Health       Date:  2015-05-14       Impact factor: 9.308

3.  Racial-Ethnic Disparities in Uptake of New Hepatitis C Drugs in Medicare.

Authors:  Jeah Jung; Roger Feldman
Journal:  J Racial Ethn Health Disparities       Date:  2016-12-07

4.  "Know More Hepatitis:" CDC's National Education Campaign to Increase Hepatitis C Testing Among People Born Between 1945 and 1965.

Authors:  Cynthia Jorgensen; C Amanda Carnes; Alycia Downs
Journal:  Public Health Rep       Date:  2016 May-Jun       Impact factor: 2.792

5.  Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease.

Authors:  Andrew J Leidner; Harrell W Chesson; Philip R Spradling; Scott D Holmberg
Journal:  Appl Health Econ Health Policy       Date:  2017-02       Impact factor: 2.561

6.  Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.

Authors:  Alexis P Chidi; Cindy L Bryce; Julie M Donohue; Michael J Fine; Douglas P Landsittel; Larissa Myaskovsky; Shari S Rogal; Galen E Switzer; Allan Tsung; Kenneth J Smith
Journal:  Value Health       Date:  2016-03-24       Impact factor: 5.725

7.  Strategies for Improving Hepatitis C Treatment Access in the United States: State Officials Address High Drug Prices, Stigma, and Building Treatment Capacity.

Authors:  Shashi N Kapadia; Carrie D Johnston; Kristen M Marks; Bruce R Schackman; Erika G Martin
Journal:  J Public Health Manag Pract       Date:  2019 May/Jun

8.  Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease.

Authors:  Andrew J Leidner; Harrell W Chesson; Fujie Xu; John W Ward; Philip R Spradling; Scott D Holmberg
Journal:  Hepatology       Date:  2015-03-16       Impact factor: 17.425

9.  Coverage for hepatitis C drugs in Medicare Part D.

Authors:  Jeah Kyoungrae Jung; Roger Feldman; Chelim Cheong; Ping Du; Douglas Leslie
Journal:  Am J Manag Care       Date:  2016-05       Impact factor: 2.229

10.  Hospitalizations for Autoimmune Hepatitis Disproportionately Affect Black and Latino Americans.

Authors:  Jason W Wen; Michael A Kohn; Robert Wong; Ma Somsouk; Mandana Khalili; Jacquelyn Maher; Michele M Tana
Journal:  Am J Gastroenterol       Date:  2018-01-30       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.